

Bibliography and Suggested Reading

The Expanding Armamentarium for EGFR-Mutated Metastatic NSCLC: Case-Driven Strategies for the Community-Based Clinician

Aggarwal C, Marmarelis ME, Hwang WT, et al. Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. *JCO Precis Oncol*. 2023 Jul;7:e2300191.

Aggarwal C, Davis CW, Mick R, et al. Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. *JCO Precis Oncol*. 2018;2018:PO.18.00107.

Bar J, Peled N, Schokrpur S, et al. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-Line Setting (UNICORN). *J Thorac Oncol*. 2023 Feb;18(2):169-180.

Basse C, Chabanol H, Bonte PE, et al. Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon 20 ins: towards a proactive, multidisciplinary approach. *Lung Cancer*. 2022 Nov;173:116-123.

Besse B, et al. LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study. Presented at: 2024 European Society of Medical Oncology Annual Congress; September 13-17, 2024; Barcelona, Spain. Abstract LBA55.

Califano R, Passaro A, Tan JL, et al. Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2. *J Clin Oncol*. 2025;43:8639.

Campelo MRG, et al. 5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study. Presented at: European Lung Cancer Congress; March 20-23, 2024; Prague, Czech Republic. Abstract 5MO.

Cho BC, Felip E, Hayashi H, et al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. *Future Oncol*. 2022 Feb;18(6):639-647.

Cho BC, Lu S, Felip E, et al; MARIPOSA Investigators. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. *N Engl J Med*. 2024 Oct 24;391(16):1486-1498.

Cho B, et al. LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial. *Ann Oncol*. 2023;34:S1306.

Cho BC, Han JY, Kim SW, et al. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. *J Thorac Oncol*. 2022 Apr;17(4):558-567.

Chhouri H, Alexandre D, Grumolato L. Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer. *Cancers*. 2023; 15(2):504.

Choudhury NJ, Marra A, Sui JSY, et al. Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers. *J Thorac Oncol.* 2023 Apr;18(4):463-475.

Conti C, et al. BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC. Presented at: American Association of Cancer Research Annual Meeting; April 10-15, 2021; Philadelphia, Pennsylvania. Abstract 1262.

Gadgeel S, Cho BC, Lu S, et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC: Longer follow-up of the MARIPOSA study. Presented at: World Conference on Lung Cancer; September 7-10, 2024; San Diego, California. Abstract OA02.03.

Girard N, et al. Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations. Presented at: World Conference on Lung Cancer. September 8-14, 2021; Virtual Meeting. Mini-Oral Presentation #3390.

Girard N, et al. Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial. Presented at: European Lung Cancer Congress; March 26-29, 2025; Paris, France. Abstract 10MO.

Haura EB. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). American Society of Clinical Oncology (ASCO) Annual Meeting; May 31-June 4, 2019; Chicago, Illinois. Abstract 9009.

Hofmarcher T, Malmberg C, Lindgren P. A global analysis of the value of precision medicine in oncology - The case of non-small cell lung cancer. *Front Med (Lausanne).* 2023 Feb 20;10:1119506.

Iams WT, Mackay M, Ben-Shachar R, et al. Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort. *JAMA Netw Open.* 2024 Jan 2;7(1):e2351700.

IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer. International Association for the Study of Lung Cancer. Updated February 2023. Accessed May 2025. <https://www.iaslc.org/iaslc-atlas-molecular-testing-targeted-therapy-lung-cancer>.

Irmer D, Funk JO, Blaukat A. EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy. *Oncogene.* 2007 Aug 23;26(39):5693-701.

Janne P, Planchard D, Cheng Y, et al. PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2). *J Thorac Oncol.* 2023;18(11):S36-S37.

Janning M, Süptitz J, Albers-Leischner C, et al.; National Network Genomic Medicine Lung Cancer (nNGM). Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). *Ann Oncol.* 2022 Jun;33(6):602-615.

Jordan EJ, Kim HR, Arcila ME, et al. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. *Cancer Discov.* 2017 Jun;7(6):596-609.

Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. *Cancer Sci*. 2016 Sep;107(9):1179-86.

Kurzrock R, Chaudhuri AA, Feller-Kopman D, et al. Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: a review. *Cancer Metastasis Rev*. 2024 Dec;43(4):1217-1231.

Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. *J Clin Oncol*. 2010 Mar 10;28(8):1351-7.

Leighl NB, et al. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. *J Clin Oncol*. 2024;42:3593-3605.

Leighl NB, et al. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. *J Clin Oncol*. 2024;42:3593-3605.

Leighl NB, Page RD, Raymond VM, et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. *Clin Cancer Res*. 2019 Aug 1;25(15):4691-4700.

Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. *Br J Cancer*. 2019 Oct;121(9):725-737.

Levy BP, et al. Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO). *J Clin Oncol*. 2025;43:8513-8513.

Lopes G, et al. Preventing Infusion-related Reactions With Intravenous Amivantamab: Primary Results From SKIPPirr, a Phase 2 Study. World Conference on Lung Cancer; September 7-10, 2024; San Diego, California. Abstract MA12.08.

Lu S, Wang J, Yang N, et al. Savolitinib (savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and *MET*-amplification (*METamp*) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): results from a randomized phase 3 SACHI study. *J Clin Oncol*. 2025;43(suppl 17):LBA8505.

Mazieres J, Drilon A, Lusque A, Mhanna L, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol*. 2019 Aug 1;30(8):1321-1328.

Moore SL, Chiu ML, Bushey BS, et al. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. *Cancer Res*. 2016 Jul 1;76(13):3942-53.

National Comprehensive Cancer Network. Non-small Cell Lung Cancer (Version 8.2025). Updated August 15, 2025. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed August 2025.

Nogami N, Barlesi F, Socinski MA, et al. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. *J Thorac Oncol*. 2022 Feb;17(2):309-323.

Offin M, Somwar R, Rekhtman N, et al. Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. *JCO Precis Oncol*. 2018;2:PO.18.00126.

Pascual J, Attard G, Bidard FC, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. *Ann Oncol*. 2022 Aug;33(8):750-768.

Passaro A, Wang J, Wang Y, et al; MARIPOSA-2 Investigators. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. *Ann Oncol*. 2024 Jan;35(1):77-90.

Passaro A, Mok T, Peters S, et al. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. *J Thorac Oncol*. 2021 May;16(5):764-773.

Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. *J Clin Oncol*. 2021 Oct 20;39(30):3391-3402.

Pennell NA, Mutebi A, Zhou ZY, et al. Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model. *JCO Precis Oncol*. 2019 Dec;3:1-9.

Piotrowska Z, Passaro A, Nguyen D, et al; REZILIENT1 Investigators. Ziplertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab. *J Clin Oncol*. 2025 Jul 20;43(21):2387-2397.

Piotrowska Z, Isozaki H, Lennerz JK, et al. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. *Cancer Discov*. 2018 Dec;8(12):1529-1539.

Pirker R, Herth FJ, Kerr KM, et al; European EGFR Workshop Group. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. *J Thorac Oncol*. 2010 Oct;5(10):1706-13.

Planchard D, Feng PH, Karaseva N, et al. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. *ESMO Open*. 2021 Oct;6(5):100271.

Planchard D, Jänne PA, Cheng Y, et al; FLAURA2 Investigators. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. *N Engl J Med*. 2023 Nov 23;389(21):1935-1948.

Popat, S. et al. LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2. *Ann Oncol*. 2024;35:S1244-S1245.

Ramalingam SS, Vansteenkiste J, Planchard D, et al; FLAURA Investigators. Overall Survival with Osimertinib in Untreated, *EGFR*-Mutated Advanced NSCLC. *N Engl J Med*. 2020 Jan 2;382(1):41-50.

Remon J, Hendriks LEL, Cardona AF, et al. *EGFR* exon 20 insertions in advanced non-small cell lung cancer: A new history begins. *Cancer Treat Rev*. 2020 Nov;90:102105.

Riess JW, Gandara DR, Frampton GM, et al. Diverse *EGFR* Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. *J Thorac Oncol*. 2018 Oct;13(10):1560-1568.

Rolfo C, Mack P, Scagliotti GV, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. *J Thorac Oncol*. 2021 Oct;16(10):1647-1662.

Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. *Ann Oncol*. 2019 May 1;30(5):839-844.

Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. *J Clin Oncol*. 2007 Dec 1;25(34):5390-6.

Shum E, et al. Emerging evidence of activity of BLU-945 in patients with advanced *EGFR*-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1/2 SYMPHONY study. Presented at: American Association of Cancer Research Annual Meeting; April 8-13, 2022; New Orleans, Louisiana. Abstract CT184.

Soria JC, Ohe Y, Vansteenkiste J, et al; FLAURA Investigators. Osimertinib in Untreated *EGFR*-Mutated Advanced Non-Small-Cell Lung Cancer. *N Engl J Med*. 2018 Jan 11;378(2):113-125.

Soria JC, Felip E, Cobo M, et al; LUX-Lung 8 Investigators. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. *Lancet Oncol*. 2015 Aug;16(8):897-907.

Soria JC, Ohe Y, Vansteenkiste J, et al; FLAURA Investigators. Osimertinib in Untreated *EGFR*-Mutated Advanced Non-Small-Cell Lung Cancer. *N Engl J Med*. 2018 Jan 11;378(2):113-125.

U.S. National Library of Medicine. A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA). ClinicalTrials.gov identifier: NCT04487080. Updated August 19, 2025. Accessed August 2025. <https://clinicaltrials.gov/study/NCT04487080>.

U.S. National Library of Medicine. Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (*EGFR*)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (COCOON). ClinicalTrials.gov identifier: NCT06120140. Updated August 26, 2025. Accessed August 2025. <https://clinicaltrials.gov/study/NCT06120140>.

Valdiviezo N, et al. MA12.04 FLAURA2: Impact of Tumor Burden on Outcomes of 1L Osimertinib ± Chemotherapy in Patients with *EGFR*-mutated Advanced NSCLC. *J Thorac Oncol*. 2024;19(10):S102.

Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. *Oncologist*. 2006 Oct;11(9):1010-7.

Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. *Mol Cancer Ther*. 2020 Oct;19(10):2044-2056.

Westover D, Zugazagoitia J, Cho BC, et al. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. *Ann Oncol*. 2018 Jan 1;29(suppl_1):i10-i19.

Yang JCH, et al. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. *J Clin Oncol*. 2023;41:LBA9000-LBA9000.

Yang JCH, Kim YJ, Lee SH, et al. Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: final overall survival (OS) from the phase III MARIPOSA study. Presented at: European Lung Cancer Congress; March 26-29, 2025; Paris, France. Abstract #40.

Yang J, et al. FLAURA2: Resistance, and Impact of Baseline TP53 Alterations in Patients Treated With 1L Osimertinib ± Platinum-Pemetrexed. Presented at: World Conference on Lung Cancer; September 7-10, 2024; San Diego, California. Abstract MA12.03.

Yu H, Brustugun OT, Ekman S, et al. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer. *Clin Lung Cancer*. 2021 Jul;22(4):e555-e562.

Yu H, et al. 1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib. *Ann Oncol*. 2021;32:S978-S979.

West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019 Jul;20(7):924-937.

Zhou F, Guo H, Xia Y, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. *Nat Rev Clin Oncol*. 2025 Feb;22(2):95-116.